OMGA Stock Price, Omega Therapeutics, Inc. Quote, Chart

Market Summary

USD2.41+0.03

Market Closed

1.26%

OMGA Stock Price

View Fullscreen

OMGA RSI Chart

OMGA Valuation

Market Cap

132.9M

Price/Earnings (Trailing)

-1.44

Price/Sales (Trailing)

26.92

Price/Free Cashflow

-1.7

OMGA Price/Sales (Trailing)

OMGA Profitability

Return on Equity

-223.14%

Return on Assets

-50.24%

Free Cashflow Yield

-58.72%

OMGA Fundamentals

OMGA Revenue

Revenue (TTM)

4.9M

Rev. Growth (Yr)

357.36%

Rev. Growth (Qtr)

138.75%

OMGA Earnings

Earnings (TTM)

-92.3M

Earnings Growth (Yr)

20.37%

Earnings Growth (Qtr)

0.42%

Breaking Down OMGA Revenue

Last 7 days

23.0%

Last 30 days

-5.9%

Last 90 days

-43.8%

Trailing 12 Months

-72.6%

How does OMGA drawdown profile look like?

OMGA Financial Health

Current Ratio

2.87

Debt/Equity

0.34

Debt/Cashflow

-5.41

OMGA Investor Care

Shares Dilution (1Y)

0.24%

Diluted EPS (TTM)

-1.66

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	4.9M	0	0	0
2023	2.3M	2.6M	2.8M	3.1M
2022	626.4K	1.1M	1.6M	2.1M
2021	0	0	0	144.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Omega Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jun 02, 2023	young richard a	sold	-40,000	8.00	-5,000	-
May 01, 2023	young richard a	sold	-40,000	8.00	-5,000	-
Apr 06, 2023	young richard a	sold	-40,000	8.00	-5,000	-
Mar 17, 2023	young richard a	sold	-80,000	8.00	-10,000	-
Feb 27, 2023	flagship pioneering inc.	bought	11,525,200	5.78	1,993,990	-
Feb 27, 2023	flagship pioneering inc.	bought	7,683,490	5.78	1,329,320	-
Jan 10, 2023	young richard a	sold	-160,000	8.00	-20,000	-
Sep 14, 2022	young richard a	sold	-80,000	8.00	-10,000	-
Feb 01, 2022	karande mahesh	acquired	5,989	0.53	11,300	president and ceo
Aug 03, 2021	berry david a	bought	902,394	17.00	53,082	-

Which funds bought or sold OMGA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	Colony Group, LLC	new	-	25,000	25,000	-%
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-94,096	-	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.92	-3,130	8,943	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	1,137	1,114,520	1,194,080	-%
May 15, 2024	HarbourVest Partners LLC	unchanged	-	2,247,750	12,819,200	5.85%
May 15, 2024	MARSHALL WACE, LLP	new	-	217,346	217,346	-%
May 15, 2024	AMUNDI	sold off	-100	-110,921	-	-%
May 15, 2024	Flagship Pioneering Inc.	unchanged	-	18,704,400	106,673,000	7.00%
May 15, 2024	683 Capital Management, LLC	unchanged	-	73,600	419,750	0.03%
May 15, 2024	Tower Research Capital LLC (TRC)	added	26.82	6,556	18,743	-%

Are Funds Buying or Selling OMGA?

Are funds buying OMGA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OMGA

No. of Funds

Unveiling Omega Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 12, 2024	fmr llc	-	0	SC 13G/A
Feb 09, 2024	harbourvest partners l.p.	6.4%	3,512,110	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Mar 10, 2023	fmr llc	-	0	SC 13G/A
Feb 27, 2023	flagship ventures fund v, l.p.	2.0%	1,088,470	SC 13D/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 14, 2022	harbourvest partners l.p.	5.5%	2,647,059	SC 13G
Feb 09, 2022	fmr llc	-	0	SC 13G

Recent SEC filings of Omega Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 06, 2024	10-Q	Quarterly Report
May 06, 2024	8-K	Current Report
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 19, 2024	PRE 14A	PRE 14A
Apr 16, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report
Mar 28, 2024	8-K	Current Report
Feb 12, 2024	SC 13G/A	Major Ownership Report
Feb 09, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Omega Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.57	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Omega Therapeutics, Inc. News

Latest updates

Omega Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)										(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	138.7%	2,360	989	831	759	516	735	595	476	268	-
Operating Expenses	5.2%	22,811	21,688	23,734	31,599	26,334	31,702	26,580	26,330	20,227	20,808
S&GA Expenses	-100.0%	-	6,157	7,869	6,206	5,954	7,036	5,198	6,202	5,406	5,727
R&D Expenses	-1.9%	15,415	15,715	16,475	25,012	19,968	26,879	20,670	19,387	14,191	14,644
Interest Expenses	-32.0%	331	487	684	957	682	248	184	-55.00	-155	-571
Net Income	0.4%	-20,129	-20,214	-22,248	-29,687	-25,279	-30,826	-25,799	-25,912	-20,164	-20,854
Net Income Margin	40.7%	-18.69*	-31.48*	-38.04*	-42.85*	-46.44*	-49.53*	-58.28*	-77.08*	-119.67*	-474.17*
Free Cashflow	32.3%	-12,335	-18,211	-23,724	-23,581	-28,403	-24,529	-25,163	-26,701	-23,502	-16,156

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-10.1%	184	204	218	229	156	146	170	193	217	233	243	130	28.00
Current Assets	-21.1%	71.00	90.00	102	125	149	138	161	183	206	229	239	125	24.00
Cash Equivalents	-12.3%	60.00	68.00	82.00	106	105	71.00	77.00	91.00	106	186	234	122	23.00
Net PPE	-5.6%	5.00	5.00	5.00	6.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	3.00
Liabilities	-2.7%	142	146	142	133	33.00	40.00	36.00	36.00	36.00	33.00	23.00	22.00	17.00
Current Liabilities	-7.9%	25.00	27.00	27.00	34.00	18.00	22.00	15.00	14.00	14.00	12.00	14.00	12.00	8.00
Long Term Debt	-6.6%	14.00	15.00	16.00	12.00	14.00	17.00	20.00	20.00	20.00	20.00	7.00	9.00	9.00
LT Debt, Current	0%	4.00	4.00	4.00	8.00	6.00	3.00	-	-	-	-	5.00	3.00	3.00
LT Debt, Non Current	-100.0%	-	15.00	16.00	12.00	14.00	17.00	20.00	20.00	20.00	20.00	7.00	9.00	9.00
Shareholder's Equity	-28.7%	41.00	58.00	76.00	96.00	123	106	134	157	181	201	220	-	-
Retained Earnings	-6.0%	-354	-334	-314	-292	-262	-237	-206	-180	-154	-134	-113	-95.12	-66.22
Additional Paid-In Capital	0.9%	396	393	390	388	386	344	341	339	337	335	334	3.00	2.00
Shares Outstanding	0.0%	55.00	55.00	55.00	55.00	55.00	48.00	48.00	48.00	48.00	48.00	14.00	5.00	-
Float	-	-	-	-	140	-	-	-	80.00	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	31.0%	-11,800	-17,100	-23,000	-23,289	-28,111	-24,237	-24,835	-26,093	-23,350	-15,956	-16,496	-14,608	-10,549	-	-	-
Share Based Compensation	62.4%	3,431	2,113	2,280	2,178	2,222	2,122	1,974	2,053	1,604	1,182	1,123	685	194	-	-	-
Cashflow From Investing	108.6%	4,465	2,140	-724	24,049	22,050	17,652	10,588	11,267	-57,567	-39,132	-353	-866	-48.00	-	-	-
Cashflow From Financing	-165.8%	-1,070	1,625	-8.00	219	39,987	586	4.00	35.00	83.00	7,295	128,713	118	125,413	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

OMGA Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Collaboration revenue	$ 2,360	$ 516
Operating expenses:
Research and development	15,415	20,091
General and administrative	7,396	6,243
Total operating expenses	22,811	26,334
Loss from operations	(20,451)	(25,818)
Other Income (expense), net:
Interest income, net	331	682
Other expense, net	(9)	(143)
Total other income, net	322	539
Net loss	$ (20,129)	$ (25,279)
Net loss per common stock attributable to common stockholders, basic	$ (0.36)	$ (0.5)
Net loss per common stock attributable to common stockholders, diluted	$ (0.36)	$ (0.5)
Weighted-average common stock used in net loss per share attributable to common stockholders, basic	55,150,507	50,627,287
Weighted-average common stock used in net loss per share attributable to common stockholders, diluted	55,150,507	50,627,287
Comprehensive loss:
Net Income (Loss)	$ (20,129)	$ (25,279)
Other comprehensive income (loss):
Unrealized gain on marketable securities	14	251
Comprehensive loss	$ (20,115)	$ (25,028)

OMGA Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 60,033	$ 68,443
Marketable securities		4,986
Accounts receivable, due from related party	1,149	1,006
Accounts receivable		5,125
Prepaid expenses and other current assets	9,708	10,324
Total current assets	70,890	89,884
Property and equipment, net	5,013	5,311
Operating lease right-of-use assets, net	107,362	108,736
Restricted cash	341	341
Other assets	74	94
Total assets	183,680	204,366
Current liabilities:
Accounts payable	1,579	1,620
Accrued expenses	4,492	7,914
Other current liabilities	2,620	1,972
Lease liabilities, current	11,989	11,300
Long-term debt, current portion	4,000	4,000
Total current liabilities	24,680	26,806
Lease liabilities, non-current	97,729	98,243
Long-term debt, net	13,897	14,885
Other liabilities	6,020	6,416
Total liabilities	142,326	146,350
Commitments and contingencies (Note 9)
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value; 200,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 55,154,985 and 55,144,982 issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	55	55
Additional paid-in capital	396,062	392,609
Accumulated other comprehensive loss		(14)
Accumulated deficit	(354,763)	(334,634)
Total stockholders' equity	41,354	58,016
Total liabilities and stockholders' equity	$ 183,680	$ 204,366

About Omega Therapeutics, Inc.

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Mahesh Karande
WEBSITE	https://omegatherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	116

Omega Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Omega Therapeutics, Inc.? What does OMGA stand for in stocks?

OMGA is the stock ticker symbol of Omega Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Omega Therapeutics, Inc. (OMGA)?

As of Fri May 17 2024, market cap of Omega Therapeutics, Inc. is 132.92 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OMGA stock?

You can check OMGA's fair value in chart for subscribers.

What is the fair value of OMGA stock?

You can check OMGA's fair value in chart for subscribers. The fair value of Omega Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Omega Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OMGA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Omega Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether OMGA is over valued or under valued. Whether Omega Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Omega Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OMGA.

What is Omega Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, OMGA's PE ratio (Price to Earnings) is -1.44 and Price to Sales (PS) ratio is 26.92. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OMGA PE ratio will change depending on the future growth rate expectations of investors.